Related Experiment Videos
Translational regulation by the p210 BCR/ABL oncoprotein
Danilo Perrotti1, Bruno Calabretta
1Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics and the Comprehensive Cancer Center, The Ohio State University, Columbus OH 43210, USA. perrotti-1@medctr.osu.edu
Oncogene
|April 20, 2004
Summary
Oncogenic proteins regulate mRNA translation to control protein levels. Targeting RNA-binding proteins in chronic myelogenous leukemia may offer new therapeutic strategies for leukemic cell survival and differentiation.
Area of Science:
- Molecular Biology
- Cancer Biology
- Hematology
Background:
- Oncogenic proteins can rapidly modulate protein levels by regulating specific mRNA translation rates.
- RNA-binding proteins with translation regulatory activity are upregulated in the blast crisis of chronic myelogenous leukemia (CML).
- CML blast crisis represents the most aggressive stage of the disease.
Purpose of the Study:
- To investigate the role of RNA-binding proteins in CML pathogenesis.
- To identify specific mRNA targets regulated by these proteins.
- To explore therapeutic strategies targeting these regulatory mechanisms.
Main Methods:
- Identification and characterization of RNA-binding proteins overexpressed in CML blast crisis.
- Analysis of mRNA targets translationally regulated by these proteins.
- Perturbation of RNA-binding protein activity in BCR/ABL-expressing cells.
Main Results:
- Several RNA-binding proteins with translation regulatory activity were identified in CML blast crisis.
- Perturbing the activity of these proteins reduced the leukemogenic potential of BCR/ABL-expressing cells.
- Key mRNA targets, including c/ebp alpha and mdm2, were identified, which are relevant to leukemic cell differentiation and survival.
Conclusions:
- RNA-binding proteins play a significant role in CML progression by regulating translation of specific mRNAs.
- Targeting these RNA-binding proteins or their mRNA targets presents a potential therapeutic avenue for CML.
- Modulating translation rates of specific mRNAs could be a novel strategy for cancer therapy.